Compare Stocks

→ One trade. One ticker. One week. (From Wealthpin Pro) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$12.76 +7.4%	$10.44	$5.42 ▼ $22.49	$140.49M	1.59	268,207 shs	489,991 shs
IMRA IMARA		$17.12	$0.97 ▼ $6.32	$165.80M	1.09	138,364 shs	271,700 shs
KRON Kronos Bio	$0.96 +1.1%	$1.15	$0.73 ▼ $2.29	$57.70M	1.82	302,912 shs	883,997 shs
XBIT XBiotech	$8.07 -1.3%	$7.40	$3.05 ▼ $9.96	$245.74M	1.45	62,673 shs	64,851 shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+3.61%	+18.93%	+5.26%	+30.97%	-19.62%
IMRA IMARA	0.00%	0.00%	0.00%	0.00%	0.00%
KRON Kronos Bio	-1.04%	-12.84%	-25.20%	-19.49%	-26.92%
XBIT XBiotech	+2.89%	-8.71%	+9.07%	+80.97%	+138.48%

Claim Your Complimentary Bitcoin Reward (Ad)

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.1776 of 5 stars	3.4	1.0	0.0	0.0	1.3	1.7	0.6
IMRA IMARA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	3.2237 of 5 stars	3.5	4.0	0.0	0.0	0.6	4.2	1.3
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.75	Moderate Buy	$27.75	117.48% Upside
IMRA IMARA	N/A	N/A	N/A	N/A
KRON Kronos Bio	3.00	Buy	$4.25	342.71% Upside
XBIT XBiotech	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest XBIT, KRON, IMRA, and ANVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/21/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
2/28/2024	ANVS Annovis Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.73) per share	N/A
IMRA IMARA	N/A	N/A	N/A	75.24	$3.44 per share	N/A
KRON Kronos Bio	$6.29M	9.17	N/A	N/A	$2.73 per share	0.35
XBIT XBiotech	$4.01M	61.28	N/A	N/A	$7.19 per share	1.12

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$56.20M	-$6.22	N/A	N/A	N/A	N/A	-446.06%	-257.97%	5/9/2024 (Estimated)
IMRA IMARA	$1.49M	$0.05	126.40	N/A	N/A	N/A	2.12%	2.00%	N/A
KRON Kronos Bio	-$112.67M	-$1.95	N/A	N/A	N/A	-1,791.87%	-58.79%	-45.03%	5/8/2024 (Estimated)
XBIT XBiotech	-$24.56M	-$0.82	N/A	∞	N/A	N/A	-10.82%	-10.52%	5/8/2024 (Estimated)

Latest XBIT, KRON, IMRA, and ANVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/29/2024	Q4 2023	ANVS Annovis Bio	N/A	-$1.09	-$1.09	$0.15	N/A	N/A
3/21/2024	Q4 2023	KRON Kronos Bio	-$0.51	-$0.43	+$0.08	-$0.43	$1.50 million	$2.29 million
3/15/2024	Q4 2023	XBIT XBiotech	N/A	-$0.16	-$0.16	-$0.16	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
IMRA IMARA	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	2.39	2.39
IMRA IMARA	N/A	48.98	48.98
KRON Kronos Bio	N/A	7.24	7.24
XBIT XBiotech	N/A	33.07	33.07

Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
IMRA IMARA	49.28%
KRON Kronos Bio	64.09%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	38.30%
IMRA IMARA	37.30%
KRON Kronos Bio	23.40%
XBIT XBiotech	28.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	6	11.01 million	6.79 million	Optionable
IMRA IMARA	41	26.23 million	16.45 million	Not Optionable
KRON Kronos Bio	62	60.10 million	46.03 million	Optionable
XBIT XBiotech	82	30.45 million	21.80 million	Optionable

XBIT, KRON, IMRA, and ANVS Headlines

Source	Headline
	XBiotech Inc money.usnews.com - April 24 at 10:40 AM
	XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $7.19 americanbankingnews.com - April 18 at 4:06 AM
	XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders finance.yahoo.com - March 20 at 5:09 AM
	XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 investorplace.com - March 18 at 5:07 PM
	The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech finance.yahoo.com - March 8 at 10:02 AM
	Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma zacks.com - March 7 at 5:51 PM
	XBiotech sees highest patent filings and grants during October in Q4 2023 pharmaceutical-technology.com - February 27 at 10:00 AM
	XBIT Mar 2024 5.000 call finance.yahoo.com - February 17 at 2:32 AM
	XBiotech Inc XBIT morningstar.com - January 18 at 8:23 PM
	A top Austin biopharmaceutical company is doubling down on its Austin campus bizjournals.com - January 8 at 6:40 PM
	XBiotech to expand Austin campus with new R&D facility worldconstructionnetwork.com - January 5 at 9:18 AM
	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus finance.yahoo.com - January 4 at 9:17 AM
	ARCT, EHTH and CRTO are among after hour movers msn.com - December 15 at 10:31 PM
	Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth finance.yahoo.com - December 5 at 2:57 PM
	XBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis finanznachrichten.de - November 14 at 10:14 AM
	Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis finance.yahoo.com - November 14 at 10:14 AM
	XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel ... bakersfield.com - September 28 at 8:06 PM
	XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke finance.yahoo.com - September 26 at 12:31 PM
	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis ... bakersfield.com - August 8 at 5:23 PM
	XBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial finanznachrichten.de - August 8 at 12:23 PM
	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial finance.yahoo.com - August 8 at 12:23 PM
	XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny thestreet.com - June 30 at 8:58 AM
	XBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients finanznachrichten.de - May 23 at 8:48 PM
	FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients finance.yahoo.com - May 22 at 1:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Annovis Bio

NYSE:ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

IMARA

NASDAQ:IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Kronos Bio

NASDAQ:KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

XBiotech

NASDAQ:XBIT

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial